Live from the NIH registry
Studies recruiting near Modesto right now
Top 25 of 105 recruiting studies, sorted by proximity — each links to its official registry page
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Breast Neoplasms, Carcinoma, Ductal, Breast
N/A
Interventional 725 participants sought
Stockton Hematology Oncology Medical Group — Stockton, California (27.1 mi)
· Sponsor: Natera, Inc.
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
Renal Pelvis and Ureter Urothelial Carcinoma
Phase 2, Phase 3
Interventional 131 participants sought
Memorial Medical Center — Modesto, California (0.3 mi)
· Sponsor: National Cancer Institute (NCI)
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Breast Cancer
Phase 3
Interventional 3,960 participants sought
Memorial Medical Center — Modesto, California (0.3 mi)
· Sponsor: NRG Oncology
Pan-tumor MRD Study
Muscle Invasive Bladder Urothelial Carcinoma, Esophageal Cancer
N/A
Observational 1,350 participants sought
Stockton Hematology Oncology Med Group — Stockton, California (27.1 mi)
· Sponsor: Paradigm Health
Philips FAST SpO2 Technology With Masimo Sensors for SpO2 Monitoring in the Neonatal, Infant, and Pediatric Populations
SpO2
N/A
Interventional 100 participants sought
Paradigm Clinical Research — Modesto, California (0.3 mi)
· Sponsor: Masimo Corporation
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Phase 2, Phase 3
Interventional 613 participants sought
Memorial Medical Center — Modesto, California (0.3 mi)
· Sponsor: National Cancer Institute (NCI)
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
Migraine
Phase 3
Interventional 1,059 participants sought
Paradigm Clinical Research - Modesto, CA /ID# 280611 — Modesto, California (0.3 mi)
· Sponsor: AbbVie
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma
Phase 2, Phase 3
Interventional 992 participants sought
Kaiser Permanente- Modesto MOB II — Modesto, California (0.3 mi)
· Sponsor: National Cancer Institute (NCI)
Exactech Shoulder Post Market Clinical Follow-up Study
Osteo Arthritis Shoulders, Osteonecrosis
N/A
Observational 20,000 participants sought
Alpine Orthopaedic Medical Group — Stockton, California (27.1 mi)
· Sponsor: Exactech
Vancomycin Reduction Practices (VRP) in the NICU
Antibiotic Stewardship, Neonatal Sepsis, Late-Onset
N/A
Interventional 13 participants sought
Kaiser Permanente Modesto Medical Center — Modesto, California (0.3 mi)
· Sponsor: Children's Hospital of Philadelphia
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8
Phase 2
Interventional 240 participants sought
Memorial Medical Center — Modesto, California (0.3 mi)
· Sponsor: NRG Oncology
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Phase 3
Interventional 2,400 participants sought
Memorial Medical Center — Modesto, California (0.3 mi)
· Sponsor: SWOG Cancer Research Network
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes
Diabetes Mellitus, Type 1
Phase 3
Interventional 150 participants sought
Paradigm Clinical Research - Modesto — Modesto, California (0.3 mi)
· Sponsor: vTv Therapeutics
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
Diabetic Peripheral Neuropathic Pain
Phase 3
Interventional 734 participants sought
Paradigm Clincial Research - Modesto — Modesto, California (0.3 mi)
· Sponsor: Vertex Pharmaceuticals Incorporated
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8
Phase 3
Interventional 306 participants sought
Kaiser Permanente- Modesto MOB II — Modesto, California (0.3 mi)
· Sponsor: National Cancer Institute (NCI)
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8
Phase 3
Interventional 1,100 participants sought
Kaiser Permanente- Modesto MOB II — Modesto, California (0.3 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Phase 3
Interventional 1,978 participants sought
Memorial Medical Center — Modesto, California (0.3 mi)
· Sponsor: National Cancer Institute (NCI)
A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration
Neovascular Age-related Macular Degeneration, nAMD
Phase 3
Interventional 304 participants sought
Retinal Consultants Medical Group, Inc - Modesto (RCA) — Modesto, California (0.3 mi)
· Sponsor: Amgen
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma
Phase 3
Interventional 1,210 participants sought
Memorial Medical Center — Modesto, California (0.3 mi)
· Sponsor: National Cancer Institute (NCI)
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
Miscellaneous Neoplasm, Nos, Non-Neoplastic Condition, Nos
N/A
Interventional 535 participants sought
Saint Joseph's Medical Center — Stockton, California (27.1 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8
Phase 3
Interventional 304 participants sought
Kaiser Permanente- Modesto MOB II — Modesto, California (0.3 mi)
· Sponsor: National Cancer Institute (NCI)
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Intracranial Meningioma, Recurrent Meningioma
Phase 2
Interventional 124 participants sought
Memorial Medical Center — Modesto, California (0.3 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma
Phase 3
Interventional 360 participants sought
Memorial Medical Center — Modesto, California (0.3 mi)
· Sponsor: National Cancer Institute (NCI)
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma
Phase 2
Interventional 156 participants sought
Kaiser Permanente- Modesto MOB II — Modesto, California (0.3 mi)
· Sponsor: National Cancer Institute (NCI)
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
Phase 2
Interventional 2,000 participants sought
Kaiser Permanente- Modesto MOB II — Modesto, California (0.3 mi)
· Sponsor: National Cancer Institute (NCI)